August 22, 2013

Boehringer to make lung cancer drug available in U.S.

Boehringer Ingelheim Pharmaceuticals, with U.S. headquarters in Ridgefield, announced Thursday that Gilotrif oral tablets will become commercially available in the U.S. the week of Sept. 2.

This medication is used to treat lung cancer patients with specific mutations. An estimated 15 percent of Caucasians and 40 percent of Asians have this mutation.

Until Gilotrif becomes commercially available, patients who need the medication can enroll in the Boehringer expanded access program. Boehringer Ingelheim will provide support to healthcare professionals and patients to help with the transition process once the product becomes accessible.

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Do you use mobile banking?<>
Most Popular on Facebook
Copyright 2017 New England Business Media